Although mechanistic insights continue to evolve, the integration of SGLT2 inhibitors into AF management holds significant promise, particularly in patients with diabetes, heart failure, or obesity—conditions strongly associated with heightened NLRP3 activity. The gene discussed is NLRP3; the disease is heart failure.